WBDE(SZ:002082) Ge Long Hui·2026-01-09 08:01Core Viewpoint - Wanbangde Pharmaceutical's Alzheimer's project has been selected for a national major science and technology project led by the Shanghai Institute of Materia Medica, indicating strong governmental support for innovative drug development in China [1][2] Group 1: Project Details - Wanbangde Pharmaceutical's subsidiary has received approval for its Alzheimer's disease project under the national major science and technology project, which focuses on breakthroughs in core technologies and the development of strategic products [1] - The project aims to address the urgent clinical needs for innovative drugs targeting major chronic diseases, infectious diseases, and rare diseases [1] Group 2: Clinical Research - The company is developing a new drug, Shisuanjianma Controlled-Release Tablets, specifically for Alzheimer's disease, which is currently undergoing large-scale, high-quality Phase II/III clinical trials [2] - The clinical study employs a multi-center, randomized, double-blind, and placebo-controlled design, aiming to comprehensively evaluate the drug's efficacy and safety [2] - This study is notable for being the first in China to set dual primary efficacy endpoints and to utilize Aβ-PET imaging to observe amyloid protein deposition changes [2] Group 3: Implications for the Company - The inclusion of Shisuanjianma Controlled-Release Tablets in the national major science and technology project reflects the recognition of its potential clinical value and the company's research capabilities in the field [2] - This project is expected to enhance the company's technological level and market competitiveness in the development of drugs for neurological diseases [2] - Successful implementation of the research tasks will facilitate the comprehensive execution of related innovative drug clinical trials, ultimately benefiting a large number of Alzheimer's patients [2]